Other languages VYNE Therapeutics Inc.

Equities

VYNE

US92941V3087

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-09 pm EDT			5-day change	1st Jan Change
1.96 ^USD	0.00%		+2.08%	-15.88%

Jul. 09	VYNE Therapeutics Inc. Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development	CI
Jul. 01	VYNE Therapeutics Inc.(NasdaqCM:VYNE) added to Russell 3000E Index	CI

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

VYNE Therapeutics Inc. Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development	Jul. 09
Arvinas, Inc. Appoints Andrew Saik as Treasurer	Jun. 24
Vyne Therapeutics Announces Dosing of First Participants in Phase 1A Trial of Novel Bd2-Selective Bet Inhibitor Vyn202	Jun. 13
Top Premarket Gainers	Jun. 07
VYNE Therapeutics Inc. Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201	Jun. 05
VYNE Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09
VYNE Therapeutics Says US FDA Clears its Investigational New Drug Application for Potential Autoimmune Treatment	May. 06
Vyne Therapeutics Announces FDA Clearance of IND Application for Vyn202, A Novel Bd2-Selective Bet Inhibitor	May. 06
VYNE Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29
VYNE Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29
VYNE Therapeutics Inc. Announces Positive Biomarker Data from Successful Phase 1B Trial of VYN201 for the Treatment of Vitiligo	Jan. 10
VYNE Therapeutics Inc. Appoints Christine Borowski, Ph.D., to Its Board of Directors	Jan. 03
VYNE Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13
Wall Street Set to Open Higher Monday as Investors Parse Earnings, Await Fed Meeting	23-10-30
Investors Look Ahead to FOMC Meeting, Earnings Reports as US Futures Trend Higher Monday	23-10-30
Top Premarket Gainers	23-10-30
VYNE Therapeutics Inc. Announces Positive Data from Phase 1b Trial for Novel Bet Inhibitor VYN201 in Patients with Nonsegmental Vitiligo	23-10-30
VYNE Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14
VYNE Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11
VYNE Therapeutics Inc. Announces Selection of Development Candidate VYN202, a Potential Best-in-Class Oral Small Molecule BD2-Selective BET Inhibitor for the Treatment of Immuno-Inflammatory Conditions	23-05-01

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages VYNE Therapeutics Inc.

Equities

VYNE

US92941V3087

Other languages

Filters